The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron.

@article{Villikka1999TheEO,
  title={The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron.},
  author={K. Villikka and Kari T. Kivist{\"o} and Pertti J Neuvonen},
  journal={Clinical pharmacology and therapeutics},
  year={1999},
  volume={65 4},
  pages={377-81}
}
BACKGROUND Ondansetron is an antiemetic agent metabolized by cytochrome P450 (CYP) enzymes. Rifampin (INN, rifampicin) is a potent inducer of CYP3A4 and some other CYP enzymes. We examined the possible effect of rifampin on the pharmacokinetics of orally and intravenously administered ondansetron. METHODS In a randomized crossover study with 4 phases and a washout of 4 weeks, 10 healthy volunteers took either 600 mg rifampin (in 2 phases) or placebo (in 2 phases) once a day for 5 days. On day… CONTINUE READING